(Reuters) -The U.S. Food and Drug Administration said on Friday that it had eliminated the risk evaluation and mitigation ...

Bristol Myers (BMY) receives FDA approval for label updates for Breyanzi and Abecma, that can ease access to the cancer cell ...

Bristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has given approval to label updates ...

Enhanced treatment options, precision medicine, and advanced diagnostics are fueling growth across major markets Zollinger ...

FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety ...

Label updates have been approved by the FDA for the CAR T-cell therapies Breyanzi and Abecma in large B cell lymphoma and ...

Label changes remove Risk Evaluation and Mitigation Strategy programs and eases monitoring requirements, supporting broader ...

The RABBIT registry is supported by a joint, unconditional grant from AbbVie, Alfasigma, Amgen, Biocon, Bristol Myers Squibb, ...

In 2022, there were 2.3 million women diagnosed with breast cancer and 670,000 deaths worldwide, according to the World ...

The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...

Bristol Myers Squibb (BMS) received U.S. Food and Drug Administration (FDA) approval for label updates for its CAR T cell ...